[go: up one dir, main page]

SMT201500067B - Derivati di acilbenzene - Google Patents

Derivati di acilbenzene

Info

Publication number
SMT201500067B
SMT201500067B SM201500067T SM201500067T SMT201500067B SM T201500067 B SMT201500067 B SM T201500067B SM 201500067 T SM201500067 T SM 201500067T SM 201500067 T SM201500067 T SM 201500067T SM T201500067 B SMT201500067 B SM T201500067B
Authority
SM
San Marino
Prior art keywords
acylbenzene
derivatives
acylbenzene derivatives
Prior art date
Application number
SM201500067T
Other languages
English (en)
Italian (it)
Inventor
Takahiro Katagiri
Shigeo Yamanoi
Hidenori Namiki
Madoka Hatta
Koji Matsumoto
Kanako Takahashi
Tomomi Yoshitomi
Yuichi Ochiai
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SMT201500067B publication Critical patent/SMT201500067B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201500067T 2010-10-14 2015-03-18 Derivati di acilbenzene SMT201500067B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010231471 2010-10-14
JP2011022325 2011-02-04
PCT/JP2011/073489 WO2012050151A1 (ja) 2010-10-14 2011-10-13 アシルベンゼン誘導体

Publications (1)

Publication Number Publication Date
SMT201500067B true SMT201500067B (it) 2015-05-05

Family

ID=45938375

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500067T SMT201500067B (it) 2010-10-14 2015-03-18 Derivati di acilbenzene

Country Status (27)

Country Link
US (1) US8722711B2 (xx)
EP (1) EP2628733B1 (xx)
JP (2) JP5069813B2 (xx)
KR (1) KR101829086B1 (xx)
CN (1) CN103249726B (xx)
AU (1) AU2011314712B2 (xx)
BR (1) BR112013009043B8 (xx)
CA (1) CA2814628C (xx)
CO (1) CO6771403A2 (xx)
CY (1) CY1116303T1 (xx)
DK (1) DK2628733T3 (xx)
ES (1) ES2532706T3 (xx)
HR (1) HRP20150225T1 (xx)
IL (1) IL225724A (xx)
MX (1) MX2013004176A (xx)
MY (1) MY160300A (xx)
NZ (1) NZ610145A (xx)
PH (1) PH12013500711A1 (xx)
PL (1) PL2628733T3 (xx)
PT (1) PT2628733E (xx)
RS (1) RS53965B1 (xx)
RU (1) RU2585765C2 (xx)
SG (1) SG189320A1 (xx)
SI (1) SI2628733T1 (xx)
SM (1) SMT201500067B (xx)
TW (1) TWI487699B (xx)
WO (1) WO2012050151A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014102743A (ru) * 2011-07-29 2015-09-10 Дайити Санкио Компани, Лимитед Амидное производное, замещенное n-гетероциклическим кольцом
ES2602962T3 (es) * 2012-01-18 2017-02-23 Daiichi Sankyo Company, Limited Derivado de fenilazol sustituido
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
TW201731506A (zh) * 2016-01-19 2017-09-16 第一三共股份有限公司 糖尿病治療劑之倂用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
BR9812857A (pt) * 1997-10-06 2000-08-08 Lilly Co Eli Compostos úteis como agentes neuro-protetores
ATE375985T1 (de) * 2000-08-23 2007-11-15 Lilly Co Eli Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Gpcr 효능제
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
US20090221639A1 (en) 2006-04-06 2009-09-03 Lisa Sarah Bertram Heterocyclic GPCR Agonists
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
JP5546542B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 アミド誘導体
JP5546543B2 (ja) 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
GB201006166D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
TW201305121A (zh) 2013-02-01
JPWO2012050151A1 (ja) 2014-02-24
RU2013121816A (ru) 2014-11-20
KR101829086B1 (ko) 2018-02-13
RU2585765C2 (ru) 2016-06-10
US8722711B2 (en) 2014-05-13
JP5069813B2 (ja) 2012-11-07
NZ610145A (en) 2015-02-27
IL225724A (en) 2015-10-29
EP2628733A4 (en) 2014-02-26
RS53965B1 (sr) 2015-08-31
BR112013009043A2 (pt) 2016-07-26
BR112013009043B1 (pt) 2019-06-18
CA2814628C (en) 2015-06-16
BR112013009043B8 (pt) 2019-09-17
CA2814628A1 (en) 2012-04-19
CN103249726B (zh) 2015-01-07
SG189320A1 (en) 2013-05-31
PT2628733E (pt) 2015-03-24
IL225724A0 (en) 2013-06-27
PH12013500711A1 (en) 2015-11-06
JP2012224640A (ja) 2012-11-15
CO6771403A2 (es) 2013-10-15
AU2011314712B2 (en) 2016-05-26
JP5869985B2 (ja) 2016-02-24
EP2628733A1 (en) 2013-08-21
MX2013004176A (es) 2013-10-25
HK1185082A1 (en) 2014-02-07
WO2012050151A1 (ja) 2012-04-19
US20130217733A1 (en) 2013-08-22
CY1116303T1 (el) 2017-02-08
SI2628733T1 (sl) 2015-10-30
AU2011314712A1 (en) 2013-05-02
DK2628733T3 (en) 2015-03-30
PL2628733T3 (pl) 2015-05-29
HRP20150225T1 (hr) 2015-06-19
ES2532706T3 (es) 2015-03-31
MY160300A (en) 2017-02-28
KR20130099094A (ko) 2013-09-05
TWI487699B (zh) 2015-06-11
EP2628733B1 (en) 2014-12-24
CN103249726A (zh) 2013-08-14

Similar Documents

Publication Publication Date Title
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
NL301013I2 (nl) Risankizumab
SMT201600298B (it) Derivati n3-sostituiti-n1-solfonil-5- fluoropirimidinone
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201900679T1 (it) Derivati deuterati di ivacaftor
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
PT2684880T (pt) Derivado de dispiropirrolidina
PL2614063T3 (pl) Podstawione imidazopirydazyny
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
SMT201400080B (it) Derivati di pirazinoossazepina
EP2578203A4 (en) cysteine
CO6960557A2 (es) Derivados de 2-yodo-imidazol
SMT201600405B (it) Derivati di arilalchilamminocarbossammide fluorurati
SMT201500113B (it) Processp per preparare derivati di alfa-carbossammide
PL2762466T3 (pl) Pochodna fenylu
SMT201500067B (it) Derivati di acilbenzene
SMT201400194B (it) Complesso di flurano
CO6852074A2 (es) Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida
PT2665720E (pt) Derivados de 2-metoxi-piridin-4-ilo
IT1400234B1 (it) Derivati esterei di fenilpropanoidi
UY3981Q (es) Perfil
UA21060S (uk) Профіль
UY3973Q (es) Perfil